Inaktiver Wert

Andere Sprachen BioCardia Inc Nasdaq

Aktien

US09060U1016

Schlusskurs Nasdaq Andere Börsenplätze
- ^USD	-

21.05.	BioCardia will Aktiensplit im Verhältnis 1:15 durchführen; Aktien fallen nachbörslich	MT
14.05.	Transcript : BioCardia, Inc., Q1 2024 Earnings Call, May 14, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioCardia to Implement 1-for-15 Reverse Stock Split; Shares Fall After Hours	21.05.
BioCardia Announces Reverse Stock Split	21.05.
BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	14.05.
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	09.05.
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	01.05.
BioCardia, Inc. Announces the Primary Endpoint Results of the Open Label Roll-In Cohort of the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial	01.05.
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25.04.
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25.04.
BioCardia, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27.03.
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20.03.
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13.03.
BioCardia, Inc. and StemCardia, Inc. Announce Long-Term Partnership to Advance StemCardia?s Investigational Pluripotent Stem Cell Product Candidate for Treatment of Heart Failure	13.03.
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12.03.
BioCardiaAnnounces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12.03.
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04.03.
Biocardia Reports Positive Interim Results from Phase III Cardiamp Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04.03.
BioCardia, Inc. announced that it expects to receive $0.874999 million in funding	09.02.
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08.02.
BioCardia, Inc. Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioCardia Inc Nasdaq

Aktien

US09060U1016

Andere Sprachen

Filter